The impact of receptor of advanced glycation end-products polymorphisms on prostate cancer progression and clinicopathological characteristics

doi:10.1111/jcmm.17025

中山醫學大學機構典藏 CSMUIR > 中山醫學大學研究成果 > 期刊論文 > Item 310902500/23888

Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/23888

Title:	The impact of receptor of advanced glycation end-products polymorphisms on prostate cancer progression and clinicopathological characteristics
Authors:	Chou, YE;Hsieh, MJ;Wang, SS;Lin, CY;Chen, YY;Ho, YC;Yang, SF
Keywords:	polymorphism;prostate cancer;RAGE
Date:	2021
Issue Date:	2022-08-05T09:44:30Z (UTC)
Publisher:	WILEY
ISSN:	1582-1838
Abstract:	The receptor for advanced glycation end products (RAGE) overexpression was suggested to be associated with prostate cancer development and poor prognosis. In this study, we focused on the correlations between the clinicopathological characteristics and susceptibility of prostate cancer and RAGE single-nucleotide polymorphisms (SNPs). In 579 prostate cancer patients, the RAGE SNPs rs1800625, rs1800624, rs2070600 and rs184003 in patients with or without grade group upgrade were analysed with real-time polymerase chain reaction. The results demonstrated that the prostate cancer patients who carried the RAGE SNPs rs2070600 'GA' genotypic variants were significantly associated with lower risk to develop grade group upgrade. Moreover, patients with the RAGE rs1800625 'TC + CC' genotypic variants were associated with higher risk of perineural invasion. In 343 prostate cancer patients who carried the RAGE rs1800625 'TC + CC' genotype without grade group upgrade were correlated with higher risk of biochemical recurrence and perineural invasion. In the analysis of TCGA database, significant differences of the RAGE mRNA level were found between the normal controls and prostate cancer patients (p < 0.0001), and the pathologic stage N1 and N0 patients (p = 0.0027). The prostate cancer patients with high RAGE expression were associated with lower overall survival rate (p = 0.025). In conclusion, our results have revealed that the RAGE SNPs rs2070600 and rs1800625 were associated with the grade group upgrade of prostate cancer and clinical status. The RAGE polymorphisms may provide as a pivotal predictor to evaluate prostate cancer disease progression and prognosis.
URI:	http://dx.doi.org/10.1111/jcmm.17025 https://www.webofscience.com/wos/woscc/full-record/WOS:000711623600001 https://ir.csmu.edu.tw:8080/handle/310902500/23888
Relation:	JOURNAL OF CELLULAR AND MOLECULAR MEDICINE ,2021,v25,issue 22, P10761-10769
Appears in Collections:	[中山醫學大學研究成果] 期刊論文

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	182	View/Open

Loading...